Group Looijenga

Medicijnen en Levenswetenschappen

1. Germ Cell and Embryonal Neoplasms 100%
2. Testicular Germ Cell Tumor 97%
3. Neoplasms 59%
4. Cisplatin 32%
5. Testicular Neoplasms 32%
6. Atlases 29%
7. MicroRNAs 29%
8. Nonseminomatous germ cell tumor 26%
9. Biomarkers 26%
10. Methylation 24%
11. Seminoma 23%
12. Testis 22%
13. Liquid Biopsy 22%
14. Mutation 22%
15. Germ Cells 22%
16. Teratoma 20%
17. Genome 20%
18. Molecular Pathology 14%
19. Tumor Biomarkers 14%
20. Recurrence 14%
21. Embryonal Carcinoma 13%
22. Drug Therapy 13%
23. Squamous Cell Carcinoma 13%
24. Oncogenes 12%
25. Therapeutics 12%
26. Embryonal Carcinoma Stem Cells 11%
27. Neuroblastoma 11%
28. Tumor Cell Line 11%
29. Serum 11%
30. Chromosomes 10%
31. Adenocarcinoma 10%
32. Sexual Development 10%
33. DNA Methylation 10%
34. Neoplasm Genes 9%
35. Meta-Analysis 9%
36. Machine Learning 9%
37. Neoplasm Metastasis 9%
38. Systematic Reviews 9%
39. Combination Drug Therapy 9%
40. Cell Line 8%
41. Pediatrics 8%
42. Chemoradiotherapy 8%
43. Pathology 8%
44. DNA 8%
45. DNA Damage 8%
46. napabucasin 8%
47. Survival 8%
48. Genes 7%
49. Urogenital Neoplasms 7%
50. Epigenomics 7%
51. Male Germ Cell Tumor 7%
52. Squamous Intraepithelial Lesions of the Cervix 7%
53. Chorionic Gonadotropin 7%
54. belinostat 7%
55. Perfusion 6%
56. Immunohistochemistry 6%
57. Familial Testotoxicosis 6%
58. Endodermal Sinus Tumor 6%
59. Methyltransferases 6%
60. In Vitro Techniques 6%
61. Demethylation 6%
62. Panobinostat 6%
63. flavanone 6%
64. Semen 6%
65. trametinib 6%
66. Mitogen-Activated Protein Kinase Kinases 6%
67. Checkpoint Kinase 1 6%
68. 46,XY Disorders of Sex Development 6%
69. Aneuploidy 5%
70. Rhabdomyosarcoma 5%
71. Sertoli Cells 5%
72. Synthetic Lethal Mutations 5%
73. Spermatogenesis 5%
74. DNA Repair-Deficiency Disorders 5%
75. Mouth Neoplasms 5%
76. Adenocarcinoma in Situ 5%
77. Cell Cycle Checkpoints 5%
78. Dogs 5%
79. Self-Examination 5%
80. Carcinoma in Situ 5%
81. TP protocol 5%
82. Circulating MicroRNA 5%
83. Homologous Recombination 5%
84. Deep Learning 5%
85. Extremities 5%
86. Disorders of Sex Development 5%
87. RNA Splicing Factors 5%
88. Poly(ADP-ribose) Polymerase Inhibitors 5%
89. Confidence Intervals 5%
90. Exome 5%
91. Long Noncoding RNA 5%
92. Paraffin 5%
93. Cervix Uteri 5%
94. hydrogen sulfite 5%
95. Ifosfamide 5%
96. Tumor-Infiltrating Lymphocytes 5%